Previous close | 2.3000 |
Open | 2.1000 |
Bid | 1.8000 |
Ask | 2.1000 |
Strike | 9.00 |
Expiry date | 2025-01-17 |
Day's range | 2.1000 - 2.1000 |
Contract range | N/A |
Volume | |
Open interest | 24 |
Explore key financial outcomes and strategic updates from Inovio Pharmaceuticals Inc's first quarter of 2024, signaling robust progress and operational efficiency.
INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the first quarter of 2024 and provided an update on recent company developments.
INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made equity grants to two newly hired employees under its 2022 Inducement Plan (the "Inducement Plan").